225 related articles for article (PubMed ID: 36770929)
21. Development of a novel five-gene immune-related risk model for the prognosis evaluation of prostate adenocarcinoma patients.
Fei H; Chen X
Am J Cancer Res; 2022; 12(5):2337-2349. PubMed ID: 35693084
[TBL] [Abstract][Full Text] [Related]
22. Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.
Liang L; Shang J; Zhang Y; Xu Y; Zhouteng Y; Wen J; Zhao Y; Feng N; Zhao R
Aging (Albany NY); 2023 Oct; 15(19):10168-10192. PubMed ID: 37788005
[TBL] [Abstract][Full Text] [Related]
23. Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer.
Ge H; Yan Y; Yan M; Guo L; Mao K
Med Sci Monit; 2020 Jun; 26():e923208. PubMed ID: 32562536
[TBL] [Abstract][Full Text] [Related]
24. TMPRSS2 Correlated With Immune Infiltration Serves as a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019.
Luo L; Zheng Y; Li M; Lin X; Li X; Li X; Cui L; Luo H
Front Genet; 2020; 11():575770. PubMed ID: 33193689
[TBL] [Abstract][Full Text] [Related]
25. Collective analysis of the expression and prognosis for LEM-domain proteins in prostate cancer.
He T; Zhang Y; Li X; Liu C; Zhu G; Yin X; Zhang Z; Zhao K; Wang Z; Zhao P; Wang K
World J Surg Oncol; 2022 Jun; 20(1):174. PubMed ID: 35650630
[TBL] [Abstract][Full Text] [Related]
26. Computer classification and construction of a novel prognostic signature based on moonlighting genes in prostate cancer.
Mei W; Jin L; Zhang B; Sun X; Yang G; Li S; Ye L
Front Oncol; 2022; 12():982267. PubMed ID: 36276080
[TBL] [Abstract][Full Text] [Related]
27. A Novel Overall Survival Prediction Signature Based on Comprehensive Research in Prostate Cancer Bone Metastases.
Hu K; Hu X; Duan Y; Li W; Qian J; Chen J
Front Med (Lausanne); 2022; 9():815541. PubMed ID: 35783639
[TBL] [Abstract][Full Text] [Related]
28. TREM2 as an independent predictor of poor prognosis promotes the migration via the PI3K/AKT axis in prostate cancer.
Gao HT; Yang Z; Sun H; Zhang Y; Wang Z; Liu WY; Wen HZ; Qu CB; Wang XL
Am J Transl Res; 2023; 15(2):779-798. PubMed ID: 36915769
[TBL] [Abstract][Full Text] [Related]
29. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
30. Identifying the tumor immune microenvironment-associated prognostic genes for prostate cancer.
Zong S; Gao J
Discov Oncol; 2024 Feb; 15(1):42. PubMed ID: 38376699
[TBL] [Abstract][Full Text] [Related]
31. Characterization of Immune-Based Molecular Subtypes and Prognostic Model in Prostate Adenocarcinoma.
Guo L; Kang Y; Xia D; Ren Y; Yang X; Xiang Y; Tang L; Ren D; Yu J; Wang J; Liang T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741849
[TBL] [Abstract][Full Text] [Related]
32. Prostate adenocarcinoma and COVID-19: The possible impacts of TMPRSS2 expressions in susceptibility to SARS-CoV-2.
Cheng J; Zhou J; Fu S; Fu J; Zhou B; Chen H; Fu J; Wei C
J Cell Mol Med; 2021 Apr; 25(8):4157-4165. PubMed ID: 33609069
[TBL] [Abstract][Full Text] [Related]
33. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
34. Analysis of competing endogenous RNA network to identify the key RNAs associated with prostate adenocarcinoma.
Li Y; Yang Z
Pathol Res Pract; 2018 Nov; 214(11):1811-1817. PubMed ID: 30195637
[TBL] [Abstract][Full Text] [Related]
35. Identification of FAM107A as a potential biomarker and therapeutic target for prostate carcinoma.
Ma YF; Li GD; Sun X; Li XX; Gao Y; Gao C; Cao KX; Yang GW; Yu MW; Wang XM
Am J Transl Res; 2021; 13(9):10163-10177. PubMed ID: 34650688
[TBL] [Abstract][Full Text] [Related]
36. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
Zheng Y; Sun H; Yang S; Liu W; Jiang G
J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
[No Abstract] [Full Text] [Related]
37. Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma.
Wen CY; Tsui KH; Chang CH; Chiu YH; Lin SA; Chu CY; Li CJ
J Oncol; 2022; 2022():9854788. PubMed ID: 35132321
[TBL] [Abstract][Full Text] [Related]
38. The Prognostic Signature and Therapeutic Value of Phagocytic Regulatory Factors in Prostate Adenocarcinoma (PRAD).
Xin S; Sun X; Jin L; Li W; Liu X; Zhou L; Ye L
Front Genet; 2022; 13():877278. PubMed ID: 35706452
[TBL] [Abstract][Full Text] [Related]
39. Integrative analysis of cancer driver genes in prostate adenocarcinoma.
Zhao X; Lei Y; Li G; Cheng Y; Yang H; Xie L; Long H; Jiang R
Mol Med Rep; 2019 Apr; 19(4):2707-2715. PubMed ID: 30720096
[TBL] [Abstract][Full Text] [Related]
40. Identification of a natural compound, sesamin, as a novel TRPM8 antagonist with inhibitory effects on prostate adenocarcinoma.
Sui Y; Li S; Zhao Y; Liu Q; Qiao Y; Feng L; Li S
Fitoterapia; 2020 Sep; 145():104631. PubMed ID: 32439453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
